© Copyright 2025 American Medical Association. All rights reserved.
The CPT® Code 86155 refers to a chemotaxis assay, which is a laboratory test that evaluates the movement of white blood cells (leukocytes) in response to chemical signals released from injured or diseased tissues. This assay is significant in assessing immune function and monitoring cancer progression, as it provides insights into how effectively the immune system can respond to pathological conditions. During the procedure, a blood sample is collected, and various methods can be employed to analyze the chemotactic response of the white blood cells. It is essential to specify the method used for the assay, as different techniques may yield varying results. Qualitative tests may utilize aggregation methods or T-maze adaptations designed for microplate formats, allowing for the observation of cell behavior in response to stimuli. Alternatively, semi-quantitative tests may involve overlaying the cells on a specific substrate and measuring changes in opalescence, which indicates the degree of cell migration. Overall, the chemotaxis assay is a valuable tool in clinical settings for understanding immune responses and the dynamics of disease progression.
© Copyright 2025 Coding Ahead. All rights reserved.
The chemotaxis assay (CPT® Code 86155) is indicated for various clinical scenarios where the evaluation of immune function is necessary. The following conditions may warrant the use of this assay:
The procedure for conducting a chemotaxis assay involves several key steps that ensure accurate measurement of white blood cell migration in response to chemical signals. The following outlines the procedural steps:
After the chemotaxis assay is completed, the results are compiled and interpreted by laboratory professionals. The findings can provide valuable information regarding the patient's immune function and disease status. There are typically no specific post-procedure care requirements for patients, as the assay is performed in a laboratory setting and does not involve invasive techniques. However, it is essential for healthcare providers to discuss the results with the patient and consider any further diagnostic or therapeutic actions based on the assay outcomes.
Short Descr | CHEMOTAXIS ASSAY | Medium Descr | CHEMOTAXIS ASSAY SPECIFY METHOD | Long Descr | Chemotaxis assay, specify method | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | CLIA Waived (QW) | No | APC Status Indicator | Conditionally packaged laboratory tests | Type of Service (TOS) | 5 - Diagnostic Laboratory | Berenson-Eggers TOS (BETOS) | T1H - Lab tests - other (non-Medicare fee schedule) | MUE | 1 | CCS Clinical Classification | 235 - Other Laboratory |
Date
|
Action
|
Notes
|
---|---|---|
Pre-1990 | Added | Code added. |